Abstracting and Indexing

  • Google Scholar
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academic Keys
  • DRJI
  • Microsoft Academic
  • Academia.edu
  • OpenAIRE

Short-Chain Fructooligosaccharides Improve Gut Microbiota Composition in Patients with Type 2 Diabetes. A randomized, Open-Label, Controlled Pilot Clinical Trial

Author(s): Gissel García, Duniesky Martínez, Josanne Soto, Lays Rodríguez, Maricela Nuez, Noraika Domínguez, Emilio F. Buchaca, Carlos Hernández, Alina Sobrino, Enrique R. Pérez, Raúl J. Cano

In this study, the impact of KestoMix, a syrup containing short-chain fructooligosaccharides (scFOS) mainly 1-kestose, on clinical parameters and gut microbiota composition in type 2 diabetes (T2DM) patients was investigated. The study was conducted as a randomized, open label, controlled clinical trial involving 60 participants. The control group consumed microcrystalline cellulose capsules, while the KestoMix group consumed KestoMix (7.2 g) twice a day for 12 weeks. Stool and blood samples were collected from all the subjects. The gut microbial composition in feces was analyzed for 20 subjects by next-generation sequencing of the V3–V4 region of the bacterial 16S rRNA gene. KestoMix did not significantly modify the basal clinical parameters associated with T2DM, but it significantly reduced serum LDL-c concentration at week 12. In terms of gut microbial composition, the presence of Firmicutes was higher than Bacteroidetes in both groups, but KestoMix intake resulted in a reduction in the Firmicutes/Bacteroidetes ratio. Also, a significant increase (p=0.046) in the Bacteroidetes/Proteobacteria ratio compared to the control group was observed at day 84. Furthermore, KestoMix intake significantly stimulated the increase in Bifidobacterium, as well as Blautia and Lactobacillus (p=0.007, p=0.034 and p=0.016, respectively). While the alpha diversity of gut microbial composition was reduced after KestoMix intake, there was a change in the existing taxonomic proportions. Overall, this study highlights the positive impact of KestoMix on gut microbiota in T2DM patients. The bifidogenic effect of KestoMix may provide long-term benefits in complications associated with T2DM and other dysbiosis.

Journal Statistics

Impact Factor: * 5.3

CiteScore: 2.9

Acceptance Rate: 11.01%

Time to first decision: 10.4 days

Time from article received to acceptance: 2-3 weeks

Discover More: Recent Articles

Grant Support Articles

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved!